← Human Trials & Peer-Reviewed Studies
Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease
Plain-language guide to PMID 31022403 (2019): open-label randomized controlled trial study of Somatostatin and Lanreotide in 305 patients.
Key Facts
- PMID
- 31022403
- Journal
- Gastroenterology
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- van Aerts RMM et al. (25 authors)
- DOI
- 10.1053/j.gastro.2019.04.018
What This Study Did, in Plain Language
What Was Tested
Researchers studied Somatostatin and Lanreotide in this randomized controlled trial publication.
Polycystic liver disease is the most common extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD).
The researchers made use of data from an open-label, randomized trial to determine the effects of lanreotide on height-adjusted liver volume (hTLV) and combined height-adjusted liver and kidney volume (hTLKV) in patients with ADPKD.
Who Took Part
According to the abstract, 305 patients were involved.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
The researchers performed a 120-week study comparing the reno-protective effects of lanreotide vs standard care in 305 patients with ADPKD (the DIPAK-1 study).
The primary endpoint was percent change in hTLV between baseline and end of treatment (week 120).
How the Study Was Run
The researchers set it up as a randomized and open-label study.
Random assignment meant chance, not the researchers, decided who got Somatostatin and who got the comparison, which limits bias.
Nothing was hidden in this open-label Somatostatin study: the patients and staff both knew the treatment.
A secondary endpoint was change in hTLKV.
What Was Measured
PubMed files the paper under topics including Cysts, Kidney, Liver, Liver Diseases, Magnetic Resonance Imaging, Organ Size and Peptides, Cyclic.
Author keywords: Drug, Liver Size, Polycystic Liver Disease and Somatostatin Analogues.
What This Means in Plain Language
The paper is a randomized and open-label study of Somatostatin and Lanreotide in 305 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2019 (Gastroenterology), a journal based in United States.
More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.
Our Notes on the Compounds
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Lanreotide: A long-acting 8-amino-acid somatostatin analog (Somatuline Depot) in the same class as octreotide.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.